- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04077671
CHF6467 SAD and MAD in Patients With Diabetic Foot Ulcer
A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of CHF6467 After Single and Repeated Ascending Doses in Subjects With Diabetic Neurophatic Foot Ulcers (DFU).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria, 1618
- Comac Medical Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject's written informed consent obtained prior to any study-related procedure;
- Male or female subject, aged 18 - 80 years (extremes inclusive), diagnosed with Type I or Type II diabetes mellitus, with glycosylated haemoglobin (HbA1c) ≤ 10%.
Female subjects of non-childbearing potential (WONCBP):
- they must report surgical sterilization (performed at least 6 months prior to screening), or
- menopause (must have had no regular menstrual bleeding for at least one year prior to screening, age ≥ 45 years and FSH at screening ≥ 40 mIU/ml).
Female subject with childbearing potential (WOCBP): they must be using one or more of the following reliable methods of contraception during the study period and at least within 90 days after the last study drug administration:
- Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- Hormonal contraception (implantable, patch, oral).
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical vaults/caps) with spermicidal foam/gel/film/cream/suppository.
- Male Partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).
- Male subjects; they must be using two effective methods of contraception during the entire study period and not donate sperm within 90 days after the last study drug administration.
Presence of at least one diabetic foot ulcer meeting the following criteria:
- Diagnosed as a full-thickness, neuropathic DFU, located at or distal to the malleolus (excluding ulcers between the toes but including those of the heel)
SAD: Present for 6 weeks to 12 months, and of 3 - 5 cm2 in area following sharp debridement, confirmed at screening.
MAD: Present for 6 weeks to 12 months, and of 3 - 6 cm2 in area following sharp debridement confirmed at screening, and of 2-5 cm2 after the 2 weeks run-in period with an area reduction compared to screening <50%.
- A minimum 1 cm margin between the qualifying study ulcer and any other ulcers on the specified foot.
- SAD: Ulcer must have a depth ≥ 5 mm at some point in its area and be graded 1A according to "The University of Texas Staging System for Diabetic Foot Ulcers" (22), with no capsule, tendon or bone exposed and no tunnelling, undermining, or sinus tracts, after the initial sharp debridement, confirmed at screening.
MAD: Ulcer must have a depth ≥ 5 mm at some point in its area and be graded 1A or 2A according to "The University of Texas Staging System for Diabetic Foot Ulcers" (22), after the initial sharp debridement, confirmed at screening.
- Subject must be able to hold the target ulcer in such a position and orientation that the study medication can be applied without significant loss of substance through run-off, until the dressing has been applied.
Adequate vascular perfusion of the affected limb demonstrated within 30 days prior to screening, as defined by at least one of the following:
- Ankle-Brachial Index (ABI) ≥ 0.9 and ≤ 1.2, confirmed by transcutaneous oxygen partial pressure (TcPO2) >50 mmHg
- Toe pressure (plethysmography) >50 mmHg
- Doppler ultrasound (biphasic or triphasic waveforms) at least on two vessels at the ankle consistent with adequate blood flow to the affected extremity, as determined by SoC.
Exclusion Criteria:
- For females only: pregnant or lactating female subject, confirmed by a positive serum pregnancy test at screening and a urine test performed on Day -1.
Subject with:
- Ulcer(s) accompanied by infected cellulitis, osteomyelitis, or clinical signs or symptoms of infection confirmed by a cultural exam made on the material taken off from the ulcer according to the technique described in the guidelines for diagnosis and management of diabetic foot infections of the Infectious Diseases Society of the Americas (IDSA) (19).
- Gangrene or necrosis on any part of the affected limb.
- Active or chronic Charcot's foot on the study limb.
- Planned vascular surgery, angioplasty or thrombolysis or previous revascularization procedure performed within 1 month prior to enrolment.
- SD only: Ulcers involving exposure of tendon, bone, or joint capsule (It is acceptable to have ulcers extending through the dermis and into subcutaneous tissue with presence of granulation tissue).
- Ulcer(s) of non-diabetic aetiology.
- Previous Lisfranc or Chopart's amputations on the same target foot.
- Actual or recent (3 weeks) antibiotic therapy for any reason.
- Bedridden subjects or subjects with a life expectancy less than one year.
- Use of any growth factor therapy in the 3 months prior to screening.
- History of malignancy in the 5 years prior to screening or those with a strong family history of cancer (e.g. familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated.
- Clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurological, psychiatric, immunological, gastrointestinal, haematological or metabolic disease that is, in the opinion of the Investigator, not stabilised or may otherwise impact subject safety or study results (in cases of doubt, the Sponsor's Clinical Research Physician should be consulted).
- Subject undergoing haemodialysis or peritoneal dialysis or with chronic renal insufficiency (plasma creatinine > 2 mg/dl).
- Subject with significantly abnormal key laboratory parameters interfering with the safety of the patient according to the PI judgement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SAD - Cohort A - CHF6467 0.3 µg/mm2
Cohort A: will be administered with CHF6467 0.3 µg/mm2 ulcer area as single dose.
|
CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
|
Experimental: SAD - Cohort B - CHF6467 1 µg/mm2
Cohort B: will be administered with 1 µg/mm2 ulcer area as single dose.
|
CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
|
Experimental: SAD - Cohort C - CHF6467 3 µg/mm2
Cohort C: will be administered with 3 µg/mm2 ulcer area as single dose.
|
CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
|
Experimental: SAD - Cohort D - CHF6467 6 µg/mm2
Cohort D: will be administered with 6 µg/mm2 ulcer area as single dose.
|
CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
|
Experimental: MAD - Cohort E - CHF6467 0.3 or 1 µg/mm2
Cohort E: will be administered with 0.3 or 1 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days).
The dose will be selected based on the SAD results.
|
CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
|
Experimental: MAD - Cohort F - CHF6467 1 or 3 µg/mm2
Cohort F: will be administered with 1 or 3 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days).
The dose will be selected based on the SAD results.
|
CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Emergent Adverse Events (TEAEs)
Time Frame: SAD: From Day 1 up to Day 28; MAD: From Day 1 up to Day 84;
|
During the SAD and the MAD, the number of events and the number and percentage of subjects experiencing TEAEs, treatment emergent ADRs, serious TEAEs, non-serious TEAEs, severe TEAEs, TEAEs leading to discontinuation of study drug and TEAEs leading to death will be presented by treatment.
|
SAD: From Day 1 up to Day 28; MAD: From Day 1 up to Day 84;
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics: AUC0-72h after single administration
Time Frame: SAD: Serial of timepoints until 72 hours post dose
|
During the SAD: Dose proportionality of CHF6467 for AUC0-72h, and classical PK parameters will be calculated
|
SAD: Serial of timepoints until 72 hours post dose
|
Pharmacodynamic: Ulcer area after multiple administration
Time Frame: MAD: From Day 1 to Days 4, 7, 10, 14, 17, 21, 24, 28, 31, 35, 38, 42, 45, 49, 52, 56, 59, 63, 66, 70, 73, 77, 80 and 84
|
MAD: Ulcer area measurements expressend in cm2 over time after multiple administration
|
MAD: From Day 1 to Days 4, 7, 10, 14, 17, 21, 24, 28, 31, 35, 38, 42, 45, 49, 52, 56, 59, 63, 66, 70, 73, 77, 80 and 84
|
Pharmacokinetics: AUC0 to infinit after multiple administration
Time Frame: MAD: Serial of timepoints at Day 1, Day 2, Day 4, Day 7, Day 10, Day 13, Day 14, Day 21 and Day 28
|
During the MAD: Dose proportionality of CHF6467 for AUC 0 to infinit, and classical PK parameters will be calculated
|
MAD: Serial of timepoints at Day 1, Day 2, Day 4, Day 7, Day 10, Day 13, Day 14, Day 21 and Day 28
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Iliya Lozev, MD, Comac Medical
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLI-06467AA1-01
- 2018-001724-19 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Neuropathic Foot Ulcers
-
Genentech, Inc.CompletedNeuropathic Diabetic Foot UlcersHungary, United Kingdom, Spain, Italy, Denmark, United States
-
VA Office of Research and DevelopmentVA Northern California Health Care SystemCompletedChronic Diabetic Foot Ulcers | Diabetic Neuropathic Ulcers | Non Healing WoundUnited States
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Calvary Hospital, Bronx, NYIntegra LifeSciences CorporationCompletedNeuropathic Diabetic Foot UlcerUnited States
-
Skilled Skin S.L.CompletedSurgical Wound | Diabetic Foot Ulcer | Skin Lesion | Pressure Ulcer | Hematoma | Venous Ulcer | Ischemic Ulcer | Arterial Ulcer | Diabetic Neuropathic Ulcer | Traumatic Ulcer | Ulcer, SkinSpain
-
Integra LifeSciences CorporationCompletedNeuropathic Diabetic Ulcer - FootUnited States, Netherlands Antilles
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
RedDress Ltd.CompletedNeuropathic Diabetic Ulcer - FootUnited States
-
Olympus Biotech CorporationCompletedDiabetic Foot Ulcer of Neuropathic OriginBelgium, Germany, Poland, Croatia, Bulgaria, Denmark, Slovakia, Hungary, Netherlands, Sweden
Clinical Trials on CHF6467 active
-
Benedetto FalsiniRecruitingOptic Pathway GliomaItaly
-
Unilever R&DCompleted
-
Novozymes A/SAnalyze & RealizeNot yet recruiting
-
Case Western Reserve UniversityHighland Instruments, Inc.RecruitingDiabetic Neuropathies | Chronic PainUnited States
-
University of California, Los AngelesRecruiting
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH); United States...CompletedChronic Low Back Pain | Chronic Neck PainUnited States
-
Chang Gung Memorial HospitalEnrolling by invitationSuspected Non-Alzheimer Disease Pathophysiology (SNAP)Taiwan
-
Lund UniversityVinnova; Antidiabetic Food Centre AFCCompleted
-
University Health Network, TorontoPatient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; Applied... and other collaboratorsActive, not recruitingDysphagiaUnited States, Canada
-
Sophiahemmet UniversityKarolinska Institutet; Linnaeus University; The Swedish School of Sport and Health... and other collaboratorsNot yet recruiting